Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyribosylribitol phosphate (PRP) is the linear capsular polysaccharide (poly-3-beta-D-ribosyl-(1->1)-D-ribitol-5-phosphate) of Haemophilus influenzae type b (Hib), a Gram-negative bacterium responsible for severe invasive infections such as meningitis, pneumonia, bacteremia, and epiglottitis, primarily in infants and young children. PRP acts as the major virulence factor of Hib by inhibiting phagocytosis and allowing the bacterium to evade the host immune system. In its native form, PRP is a T-cell-independent antigen that fails to elicit a robust or long-lasting immune response in infants under two years of age due to their immature immune systems. To overcome this limitation, PRP is chemically conjugated to carrier proteins (such as tetanus toxoid, diphtheria toxoid, or meningococcal outer membrane protein complex) to create glycoconjugate vaccines. This conjugation converts PRP into a T-cell-dependent antigen, which successfully recruits T-helper cells, promotes class switching to high-affinity IgG antibodies, and establishes immunological memory. Widespread immunization with Hib conjugate vaccines has dramatically reduced the incidence of invasive Hib disease globally.
Active immunization via glycoconjugate vaccines where PRP is covalently linked to a carrier protein. This chemical conjugation converts the T-cell-independent PRP polysaccharide into a T-cell-dependent antigen, recruiting T-helper cells to stimulate B-cell activation, class switching to high-affinity IgG antibodies, and the establishment of long-term immunological memory.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyribosylribitol phosphate (PRP).